NCT00898924已完成不适用
Evaluation of EGFR and K-ras Mutations in Patients With Stage III NSCLC Treated on CALGB 30106
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 主要终点
- Overall survival
研究概览
简要总结
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at epidermal growth factor receptor mutations and k-ras oncogene mutations in patients with stage III non-small cell lung cancer.
详细描述
OBJECTIVES:
- Determine the frequency of epidermal growth factor receptor (EGFR) and K-ras mutations in patients with stage III non-small cell lung cancer (NSCLC) treated on CALGB 30106.
- Correlate presence or absence of EGFR and/or K-ras mutations with radiographic response to treatment in these patients.
OUTLINE: Tissue samples are analyzed for epidermal growth factor receptor and K-ras mutations.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Overall survival
时间窗: Up to 3 years
Progression free survival
时间窗: Up to 3 years
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung CancerLung CancerNCT00899756Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins50
招募中
不适用
Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung CancerLung CancerNCT00899405University of California, Davis800
撤回
不适用
Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507Lung CancerNCT00907699Case Comprehensive Cancer Center
已完成
不适用
Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib TosylateLung CancerNCT01124669ECOG-ACRIN Cancer Research Group80
已完成
不适用
Study of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803Prostate CancerNCT00897351ECOG-ACRIN Cancer Research Group37